Regeneron To Double U.S. Biologics Capacity Through $3B+ Fujifilm Manufacturing Partnership

Regeneron Pharmaceuticals has announced a significant expansion of its biologics manufacturing capabilities through a new 10-year agreement with FUJIFILM Diosynth Biotechnologies. Under the deal, Regeneron will utilise Fujifilm’s advanced biopharmaceutical facility in Holly Springs, North Carolina, to produce commercial bulk drug products. This collaboration is expected to nearly double Regeneron’s U.S. manufacturing capacity, with the total investment projected to exceed $3 billion. 

“Regeneron is an American success story, with over 80 per cent of our workforce and assets in the U.S. and all of our FDA-approved medicines invented in our New York laboratories. Our innovative approach has filled our commercial and clinical pipeline with important new medicines and driven a need for even more manufacturing capacity to fulfill the promise of our science. We meet this need through increased investment in New York and North Carolina. We are proud to advance biotech innovation, which directly improves the health of people around the globe, while generating economic growth and high-paying jobs for America itself,” said Leonard Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of Regeneron. 

This strategic move complements Regeneron’s broader commitment to U.S.-based biopharma production. The company is investing approximately $3.6 billion to expand its Tarrytown, New York, campus, creating around 1,000 high-skill jobs and enhancing R&D, preclinical manufacturing, and support operations. Regeneron is also building a new fill/finish plant in Rensselaer, NY, and has purchased a large facility in Saratoga Springs for additional production and support activities.Over the past five years, Regeneron has added more than 7,000 jobs, primarily in research and manufacturing across the United States. 

Daniel Van Plew, Executive Vice President and General Manager, Industrial Operations and Product Supply at Regeneron, said, “At Regeneron, we have the privilege of making some of the best and most innovative therapeutics in the industry, and we are acutely aware of our impact on people’s lives as we work to help treat or even cure devastating diseases. We take our role seriously, and our decision to work with Fujifilm reflects our belief that they will meet our high standards and grow with us. We are excited about this unique relationship and are working to bring capacity online at Fujifilm’s biologics manufacturing facility in Holly Springs, North Carolina.”

“Partnering with Regeneron, a global leader in biotechnology and scientific innovation, is a true honour for us, as we bring together our exceptional teams and shared vision to make transformative medicine accessible to patients,” said Lars Petersen, President and Chief Executive Officer of FUJIFILM Diosynth Biotechnologies. “We are honoured that Regeneron has the trust and confidence in our teams’ ability to deliver capacity faster, ensuring continuity of supply for patients in need.”